Thus, our interdisciplinary study including cancer biology, chemical biology, bioinformatics analyses, and computational structural biology, successfully led to the discovery of the agent and its previously unknown target to induce cell death in combination with the MEK inhibitor. The gene discussed is MAP2K7; the disease is cancer.